Kewaunee Scientific Corporation (KEQU)
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Investigation
11/09/2021
Initial Lawsuit
01/31/2022
Lawsuit Progression
04/01/2022
Did Shattuck Labs, Inc. issue misleading statements regarding the termination of its 2017 collaboration agreement with Millennium Pharmaceuticals, Inc. (owned by Takeda Pharmaceutical Company, Ltd.)? On November 9, 2021, Shattuck abruptly announce the termination of its agreement with Millennium regarding SL-279252 and SL-115154.
This investors investigation page is opened for investors to gather facts, findings and track related lawsuits. We invite investors and shareholders to contribute to investigations for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed and the question asked to a court of justice. We will update this post as it unfolds.
11/09/2021
Shattuck provides its Q3 2021 financial results and multiple business updates, including the termination of its agreement with Takeda for SL-279252 and SL-115154, changes on its board of directors and initial data from its ongoing SL-172154 (SIRPα-Fc-CD40L) Phase 1 clinical trial.
“Shattuck is no longer required to satisfy any remaining performance obligations, the Company will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$13.59 | $19.04 | $-5.45 | -28.62% |
Plaintiff brings this securities class-action lawsuit on behalf of persons or entities who purchased or otherwise acquired publicly traded Shattuck securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with Shattuck’s October 2020 initial public offering; and/or (2) between October 9, 2020 and November 9, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(1) the August 8, 2017 collaboration agreement with Takeda was not solid;
(2) Takeda and Shattuck would “mutually agree” to terminate the collaboration agreement in essentially one year;
(3) as a result, Shattuck would cease to receive any future milestone, royalty, or other payments from Takeda; and
(4) as a result, defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
07/01/2022
Operative complaint
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.